RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
307.60
-21.00 (-6.39%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close328.60
Open316.60
Bid307.20 x 400800
Ask307.40 x 100
Day's Range305.00 - 316.60
52 Week Range157.00 - 529.90
Volume258,830
Avg. Volume215,799
Market Cap784.706M
Beta (3Y Monthly)0.15
PE Ratio (TTM)N/A
EPS (TTM)-0.24
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
  • GlobeNewswire3 days ago

    RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and cancer, today announced a poster presentation on YELIVA® (opaganib, ABC294640)1 for multiple myeloma at the upcoming EORTC-NCI-AACR Symposium2 on Molecular Targets and Cancer Therapeutics, on Friday, November 16th in Dublin.

  • GlobeNewswire4 days ago

    RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights

    Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA.

  • GlobeNewswire11 days ago

    RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it will report its third quarter 2018 financial results on Tuesday, November 13, 2018. The Company will host a conference call on Tuesday, November 13, 2018 at 8:30 a.m. EST to review the financial results and business highlights.

  • GlobeNewswire19 days ago

    RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018

    Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018H. pylori bacterial infection affects over 50% of the adult population.

  • GlobeNewswire23 days ago

    RedHill Biopharma to Present at the BIO-Europe 2018 Conference

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 25, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Adi Frish, Senior VP Business Development and Licensing, will present a corporate overview at the BIO-Europe 2018 Conference, on Tuesday, November 6, 2018, at 4:15 p.m. CET, at the Bella Center in Copenhagen, Denmark.

  • GlobeNewswire24 days ago

    RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection

    RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDTFinal patient assessed for primary endpoint,.

  • GlobeNewswire26 days ago

    RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018

    The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of clinical remission at week 26 (p=0.007) and key secondary and.

  • GlobeNewswirelast month

    RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 10, 2018 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswire2 months ago

    RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference

    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the Ladenburg Thalmann 2018 Healthcare Conference, on Tuesday, Oct. 2, 2018, at 10:30 a.m. ET, at the Sofitel Hotel in New York City.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D

    The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome, one of the most common gastrointestinal disorders In light ...

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma

    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that the ongoing single-arm Phase IIa study with orally-administered YELIVA® (opaganib, ABC294640)1 for the treatment of advanced cholangiocarcinoma (bile duct cancer) has achieved its pre-specified efficacy goal for the first stage of the two-stage study design, and as a result, the study will continue to its second stage, enrolling the full cohort of 39 evaluable patients. The primary efficacy endpoint of the study is defined as either partial or complete response, or stable disease at four months treatment with YELIVA®.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection

    Top-line results from the randomized, double-blind confirmatory Phase III study with TALICIA ® are expected before year’ s end The ERADICATE Hp2 study enrolled 455 patients with confirmed H. pylori infection ...

  • GlobeNewswire3 months ago

    RedHill Biopharma Reports Second Quarter 2018 Financial Results and Provides Update on Operations

    Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection on track to be announced in the fourth quarter of 2018 Positive top-line results from Phase III study with RHB-104 ...

  • GlobeNewswire3 months ago

    RedHill Biopharma to Host Second Quarter 2018 Financial Results Conference Call on August 30, 2018

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it will report its second quarter 2018 financial results on Thursday, August 30, 2018. The Company will host a conference call on Thursday, August 30, 2018 at 8:30 a.m. EDT to review the financial results and business highlights. The conference call will be broadcast live and will be available for replay on the Company's website, http://ir.redhillbio.com/events, for 30 days.

  • GlobeNewswire3 months ago

    RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a new formulation patent covering RHB-106, which is expected to be valid until at least 2033. RHB-106 is an encapsulated bowel cleanser licensed to Salix Pharmaceuticals (“Salix”), a wholly-owned subsidiary of Bausch Health Companies Inc. (NYSE: BHC and TSX: BHC).

  • Why Redhill Biopharma Ltd. Stock Is Soaring Today
    Motley Fool4 months ago

    Why Redhill Biopharma Ltd. Stock Is Soaring Today

    Redhill's late-stage Crohn's disease drug hits the mark in a late-stage trial.

  • Benzinga4 months ago

    RedHill Earns Long-Awaited Boost On Positive Crohn's Data

    REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) achieved positive top-line results in its Phase 3 study of RHB-104 in Crohn’s disease, according to a Monday press release . What Happened The drug met both primary ...

  • Reuters4 months ago

    RedHill BioPharma has positive results from Crohn's disease trial

    Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104. The study met its primary endpoint and key secondary endpoints, demonstrating the drug's superiority over a placebo in achieving remission of the gastrointestinal disease at week 26, the company said in a statement. "The proportion of patients meeting the primary endpoint was significantly greater in the RHB-104 group compared to placebo," RedHill said.